Sage Therapeutics Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis The FDA's Psychopharmaco

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The past year has been a bit stressful for this company and its shareholders.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a l

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P

Sage Therapeutics, Inc. (SAGE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in th

For bargain hunters, every stock market cloud has a silver lining. After a rough first quarter, dozens of stocks have descended to what I consider attractive levels.

Sage Therapeutics, Inc. (SAGE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in th

Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 5 0 0 Las

Upgrades Raymond James upgraded the previous rating for Starwood Property Trust Inc (NYSE:STWD) from Outperform to Strong Buy. For the fourth quarter, Starwood Property Trust had an EPS of $1.10, comp

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will

Sage Therapeutics (SAGE) said that data from a phase 2 trial showed SAGE-718 was associated with improvements on multiple tests of functioning and learning and memory in patients with…

Sage Therapeutics Inc. (NASDAQ:SAGE) shares, rose in value on Friday, 03/11/22, with the stock price down by -3.36% to the previous day’s close as strong demand from buyers drove the stock to $31.07. Actively observing the price movement in the last trading, the stock closed the session at $32.15, falling within a range of $31.02 … Sage Therapeutics Inc. (NASDAQ: SAGE) Stock Seems Like A Good Option Read More »

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 10:30am ET. A live webcast of the fireside chat can be accessed on the Investor page of Sage’s website at investor.sag